Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
107.89 +1.15 (+1.08%) 03/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 108.00 +0.11 (+0.10%) 19:52 ET
Quote Overview for Tue, Mar 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
106.30
Day High
107.95
Open 106.74
Previous Close 106.74 106.74
Volume 8,444,601 8,444,601
Avg Vol 10,880,660 10,880,660
Stochastic %K 16.62% 16.62%
Weighted Alpha +53.84 +53.84
5-Day Change -2.34 (-2.12%) -2.34 (-2.12%)
52-Week Range 62.07 - 119.96 62.07 - 119.96
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,928,224
  • Shares Outstanding, K 1,245,346
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 1,662 M
  • EBITDA $ 4,429 M
  • 60-Month Beta 0.21
  • Price/Sales 4.64
  • Price/Cash Flow 15.59
  • Price/Book 6.93

Options Overview Details

View History
  • Implied Volatility 26.59% ( -0.10%)
  • Historical Volatility 29.74%
  • IV Percentile 73%
  • IV Rank 53.88%
  • IV High 33.98% on 08/05/24
  • IV Low 17.95% on 11/07/24
  • Put/Call Vol Ratio 1.70
  • Today's Volume 9,939
  • Volume Avg (30-Day) 18,359
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 217,991
  • Open Int (30-Day) 227,598

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 1.73
  • Number of Estimates 8
  • High Estimate 1.98
  • Low Estimate 1.35
  • Prior Year -1.32
  • Growth Rate Est. (year over year) +231.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.70 +3.05%
on 03/20/25
Period Open: 111.53
119.96 -10.06%
on 03/10/25
-3.64 (-3.26%)
since 02/25/25
3-Month
88.57 +21.81%
on 01/10/25
Period Open: 93.95
119.96 -10.06%
on 03/10/25
+13.94 (+14.84%)
since 12/24/24
52-Week
62.07 +73.82%
on 05/31/24
Period Open: 72.58
119.96 -10.06%
on 03/10/25
+35.31 (+48.65%)
since 03/25/24

Most Recent Stories

More News
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation

Shares of pharma conglomerate Bayer BAYRY were down 7.1% on March 24, following a setback in the ongoing Roundup Litigation.Bayer reported that, on March 21, the jury at the Barnes Roundup trial in the...

BAYRY : 6.3400 (+4.79%)
NVO : 73.60 (-2.30%)
GILD : 107.89 (+1.08%)
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This update allows cash-paying patients or those with commercial insurance, which does...

BAYRY : 6.3400 (+4.79%)
NVO : 73.60 (-2.30%)
LLY : 852.35 (-1.45%)
GILD : 107.89 (+1.08%)
FDA Approves Novartis Drug for Rare Kidney Disease Treatment

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication.The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria.C3G...

BAYRY : 6.3400 (+4.79%)
NVS : 110.38 (-0.64%)
GILD : 107.89 (+1.08%)
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

SRPT : 73.61 (-3.56%)
BMRN : 71.53 (-0.64%)
GILD : 107.89 (+1.08%)
MRNA : 33.85 (-0.94%)
AMGN : 306.86 (-2.39%)
GILD Stock Down on Report of Cut in HIV Prevention Spending

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding for...

GILD : 107.89 (+1.08%)
GSK : 38.58 (+0.03%)
PFE : 25.55 (-2.26%)
Stocks Slip Before the Open After Fed-Fueled Rally, U.S. Economic Data and Earnings in Focus

March S&P 500 E-Mini futures (ESH25) are down -0.43%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.60% this morning, tracking losses in European equities after ECB President Christine Lagarde...

NVDA : 120.69 (-0.59%)
MU : 94.18 (-2.85%)
NKE : 66.54 (-1.26%)
RIVN : 12.36 (+1.39%)
ACN : 308.90 (+0.56%)
ESH25 : 5,617.80s (-0.79%)
SIG : 60.26 (-1.65%)
FIVE : 77.01 (-2.80%)
TSLA : 288.14 (+3.50%)
LEN : 117.74 (+0.15%)
STZ : 178.36 (-1.07%)
NQH25 : 19,450.81s (-1.16%)
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed

The company has a portfolio of HIV prevention treatments such as Biktarvy and Descovy.

QQQ : 493.46 (+0.57%)
COWZ : 55.38 (-0.34%)
GILD : 107.89 (+1.08%)
SPY : 575.46 (+0.24%)
Stocks Rally as Fed Chair Powell Says the US Economy Remains Strong

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +1.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.30%. March E-mini S&P...

GOOGL : 170.56 (+1.72%)
UAL : 78.90 (-1.65%)
AAPL : 223.75 (+1.37%)
EXPE : 176.86 (-0.80%)
$IUXX : 20,287.83 (+0.53%)
ZNM25 : 110-185 (-0.16%)
MSFT : 395.16 (+0.53%)
TSLA : 288.14 (+3.50%)
ESM25 : 5,827.25 (+0.01%)
NCLH : 20.47 (-1.06%)
RTX : 135.66 (+0.72%)
$DOWI : 42,587.50 (+0.01%)
Buy 3 U.S. Giants Flying High Year to Date Defying Severe Volatility

U.S. stock markets have been enduring severe volatility over the past month. Wall Street’s recent turmoil is broad-based. The three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite...

PGR : 274.43 (+0.16%)
GILD : 107.89 (+1.08%)
GE : 212.13 (+0.90%)
US Stock Market Update: 5 Things to Know Before the Stock Market Opens Wednesday

As the US stock market prepares to open on Wednesday, March 19 investors are bracing themselves for another day of volatility. The Federal Reserve’s interest rate decision, scheduled for later today,...

GIS : 57.79 (-0.65%)
GOOGL : 170.56 (+1.72%)
NVDA : 120.69 (-0.59%)
TSLA : 288.14 (+3.50%)
GM : 52.59 (+2.20%)
GILD : 107.89 (+1.08%)
GS : 585.94 (+1.01%)
AMZN : 205.71 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 110.11
2nd Resistance Point 109.03
1st Resistance Point 108.46
Last Price 107.89
1st Support Level 106.81
2nd Support Level 105.73
3rd Support Level 105.16

See More

52-Week High 119.96
Last Price 107.89
Fibonacci 61.8% 97.85
Fibonacci 50% 91.01
Fibonacci 38.2% 84.18
52-Week Low 62.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals